Stratified medicine for cancer therapy

Drug Discovery Today

Volumn 17, Issue 5-6, 2012, Pages 261-268

  Shaw, Emily C ^a   Johnson, Peter W M ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; B RAF KINASE; CRIZOTINIB; CYTOCHROME P450 2D6; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; NILOTINIB; OLAPARIB; PAZOPANIB; PROTEIN BCL 2; PROTEIN P53; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; CELL GROWTH; CELL SURVIVAL; CHROMOSOME 10; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA MODIFICATION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; EPIGENETICS; FAMILIAL CANCER; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICINE; MELANOMA; MOLECULAR PATHOLOGY; ONCOGENE C KIT; ONCOGENE C MYC; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRANDED DNA BREAK; STRATIFIED MEDICINE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DISCOVERY; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84857995689     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.02.004     Document Type: Review

References (70)

1. M.R. Trusheim Stratified Medicine: strategic and economic implications of combining drugs and clinical biomarkers Nat. Rev. Drug Discov. 6 2007 287 293
2. S. Castaigne All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results Blood 76 1990 1704 1709
3. B.J. Druker Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia N. Engl. J. Med. 344 2001 1031 1037
4. J. Verweij Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 2004 1127 1134
5. T.J. Lynch Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
6. P. Sunpaweravong Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma J. Cancer Res. Clin. Oncol. 131 2005 111 119
7. A.J. Ekstrand Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails Proc. Natl. Acad. Sci. U.S.A. 89 1992 4309 4313
8. D.K. Moscatello Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Res. 55 1995 5536 5539
9. D. Malkin Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms Science 250 1990 1233 1238
10. A.G. Knudson Jr. Mutation and cancer: statistical study of retinoblastoma Proc. Natl. Acad. Sci. U.S.A. 68 1971 820 823
11. J.E. Garber, and K. Offit Hereditary cancer predisposition syndromes J. Clin. Oncol. 23 2005 276 292
12. N.P. Carter Methods and strategies for analysing copy number variation using DNA microarrays Nat. Genet. 39 2007 S16 S21
13. P.J. Campbell Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing Nat. Genet. 40 2008 722 729
14. M. Kool Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features PLoS ONE 3 2008 E3088
15. Dr B. Vogelstein at AACR 101st meeting 2010. The sequence of all 185,000 coding exons in each of 100 human tumors: what has it taught us? 17-21 April, 2012, Washington, DC, USA
16. L.D. Wood The genomic landscapes of human breast and colorectal cancers Science 318 2007 1108 1113
17. S. Jones Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 2008 1801 1806
18. M.R. Stratton The cancer genome Nature 458 2009 719 724
19. G.A. Calin Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc. Natl. Acad. Sci. U.S.A. 99 2002 15524 15529
20. G.A. Calin Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers Proc. Natl. Acad. Sci. U.S.A. 101 2004 2999 3004
21. S. Sharma Epigenetics in cancer Carcinogenesis 31 2010 27 36
22. International Cancer Genome Consortium International network of cancer genome projects Nature 464 2010 993 998
23. W.Y. Chung A first look at ARFome: dual-coding genes in mammalian genomes PLoS Comput. Biol. 3 2007 E91
24. C.S. Karapetis K-ras mutations and benefit from cetuximab in advanced colorectal cancer N. Engl. J. Med. 359 2008 1757 1765
25. D.W. Parsons An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
26. Y. Kanai Genome-wide DNA methylation profiles in precancerous conditions and cancers Cancer Sci. 101 2010 36 45
27. C.M. Perou Molecular portraits of human breast tumours Nature 406 2000 747 752
28. A.A. Alizadehl Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
29. S. Shah Mutation of FOXL2 in granulosa-cell tumors of the ovary N. Engl. J. Med. 360 2009 2719 2729
30. M. Brehme Charting the molecular network of the drug target Bcr-Abl Proc. Natl. Acad. Sci. U.S.A. 106 2009 7414 7419
31. S. Ganti, and R.H. Weiss Urine metabolomics for kidney cancer detection and biomarker discovery Urol. Oncol. 29 2011 551 557
32. G. Giamas Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer Nat. Med. 17 2011 725 729
33. G. Manning The protein kinase complement of the human genome Science 298 2002 1912 1934
34. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N. Engl. J. Med. 353 2005 172 187
35. D. Watanabe Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines Br. J. Haematol. 126 2004 726 735
36. I. Pashtan Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition Cell Cycle 7 2008 2936 2941
37. T.S. Mok Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
38. F. Cappuzzo Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multi-center, placebo-controlled randomised phase II study Lancet Oncol. 11 2010 521 529
39. NICE technology appraisal number 162: Erlotinib as treatment for non-small cell lung cancer
40. K.T. Flaherty Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 363 2010 809 819
41. P. Chapman Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
42. E.L. Kwak Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N. Engl. J. Med. 363 2010 1693 1703
43. N.Z. Khokhar Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies Curr. Opin. Oncol. 23 2011 578 586
44. P. le Coutre In vitro eradication of human BCR/ABL-positive leukaemia cells with an ABL-kinase inhibitor J. Natl. Cancer Inst. 91 1999 163 168
45. D.A. Tuveson STI571 inactivation of the gastrointestinal stromal tumour c-KIT oncoprotein: biological and clinical implications Oncogene 20 2001 5054 5058
46. G.D. Demetri Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
47. C.H. Barrios Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma Cancer 2011 10.1002/cncr.26440 [Epub ahead of print]
48. R.J. Motzer Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
49. H.E. Bryant Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 916
50. H. Farmer Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 494 2005 917 921
51. P. Fong Inhibition of Poly (ADP-ribose) polymerase in tumours from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
52. K.J. Dedes Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations Cell Cycle 10 2011 1192 1199
53. P.A. Konstantinopoulos, and S.A. Cannistra Comparing poly(ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial J. Clin. Oncol. 30 2012 347 350
54. R. Brough Searching for synthetic lethality in cancer Curr. Opin. Genet. Dev. 21 2011 34 41
55. S.A. Martin DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 Cancer Cell 17 2010 235 248
56. Y. Dong Synthetic lethality through combined notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer Cancer Res. 70 2010 5465 5474
57. K. Kiyotani Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients J. Clin. Oncol. 28 2010 1287 1293
58. K. Shulman Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients Cancer 117 2011 3156 3162
59. C.F. Xu Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes J. Clin. Oncol. 29 2011 2557 2564
60. D. Bogunovic Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival Proc. Natl. Acad. Sci. U.S.A. 106 2009 20429 20434
61. P.J. Stephens Complex landscapes of somatic rearrangement in human breast cancer genomes Nature 462 2009 1005 1010
62. A.B. Turke Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17 2010 77 88
63. S.W. Jahn Multiple intratumoural KRAS mutations can clonally segregate to different lymph node metastases in colon cancer Histopathology 59 2011 342 345
64. S. Thomson Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy Clin. Exp. Metastasis 25 2008 843 854
65. I.K. Mellinghoff Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N. Engl. J. Med. 353 2005 2012 2024
66. G. Wang DNA amplification method tolerant to sample degradation Genome Res. 14 2004 2357 2366
67. P.J.T.A. Groenen Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase Histopathology 59 2011 1 7
68. S. Billah EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens Cancer Cytopathol. 119 2011 111 117
69. I.I. Wistuba Methodological and practical challenges for personalized cancer therapies Nat. Rev. Clin. Oncol. 8 2011 135 141
70. D. Cavalla, and C. Singal Retrospective clinical analysis for drug rescue: for new indications or stratified patient groups Drug Discov. Today 2011 10.1016/j.drudis.2011.09.019 [Epub ahead of print]